Dear Editor,

We isolated *Burkholderia cepacia* from blood and sputum samples of cancer patients having febrile neutropenia. *B. cepacia* was identified using Gram-negative GN REF 21341 identification card in automated VITEK^®^2 Compact (C) system (Biomeriux, North Carolina/USA). Antibiotic susceptibility results were expressed as susceptible, intermediate or resistant according to the criteria of the Clinical Laboratory Standards Institute M100-S23 (2013).\[[@ref1]\]

*B. cepacia* was isolated from blood samples collected aseptically from five patients suffering from non-Hodgkin\'s lymphoma, renal cell carcinoma, carcinoma cecum with liver metastasis, acute myeloid leukemia and periampullary carcinoma; and from good quality sputum sample of a patient suffering from carcinoma lung. Detailed clinical history along with informed consent regarding possible publication was taken from all the patients. All the isolates of *B. cepacia* were resistant to aminoglycoside antibiotics and ciprofloxacin; and were sensitive to co-trimoxazole, meropenem, piperacillin, piperacillin-tazobactam and cefepime. Five were susceptible to ceftazidime also.

The 2010 Sanford Guide recommends co-trimoxazole as the treatment of choice for this infection. In addition, it lists 5 antibiotics to which more than 60% of clinical isolates of *B. cepacia* are susceptible or that are clinically effective: Meropenem, ceftazidime, ceftibuten, chloramphenicol and trimethoprim.\[[@ref2]\] Since myelosuppression is a known side-effect of co-trimoxazole, it could not be used in our patients already having neutropenia. Adverse reactions are also more common with meropenem compared to piperacillin-tazobactam. Hence our patients were treated with intravenous piperacillin-tazobactam. The patients recovered clinically and repeat blood and sputum cultures were negative.

Over the past few decades, *Burkholderia* spp. has become an emerging opportunistic pathogen, most commonly reported in patients suffering from cystic fibrosis.\[[@ref3]\] However, it is not commonly encountered in immune-suppressed oncology patients despite their compromised state and propensity for acquiring infections caused by Gram-negative pathogens.\[[@ref4]\] There are few reports available regarding infections due to *Burkholderia* in the general oncology population. In general, *Burkholderia* manifests innate resistance to aminoglycoside antibiotics and widespread resistance to many beta-lactam agents, including extended-spectrum penicillins such as piperacillin and the 4^th^ generation cephalosporin cefepime.\[[@ref2]\] However, in our study we found that all the isolates were uniformly susceptible to piperacillin, piperacillin-tazobactam and cefepime. So the antibiogram of *Burkholderia* spp. isolated from our cancer patients, by retaining susceptibility to these three antibiotics, seemed to be slightly different from those isolated from other cases. Similar findings were reported in a study by Heo *et al.*\[[@ref5]\] They described an outbreak of *Burkholderia stabilis* in eight patients with underlying malignancies of acute lymphoblastic leukemia or acute myeloid leukemia at a university teaching hospital in Korea. Interestingly, the strains of *B. stabilis* isolated from this study were susceptible to a wider range of antibiotics, including piperacillin/tazobactam and cefepime, an uncommon occurrence for patients infected with *Burkholderia* spp.

Our findings indicate that *Burkholderia* spp. isolated from cancer patients may manifest an antibiogram different from that usually observed, by retaining susceptibility to more number of antibiotics especially to piperacillin-tazobactam and cefepime.
